Table 2.

Predictors of infliximab trough level

	B	p value	95% CI
Intercept	0.419	0.317	(− 0.410 to 1.249)
Reactive sample collection	− 0.235	0.345	(− 0.672 to 0.034)
Time in days	< − 0.001	0.767	(− 0.003 to < 0.001)
Male sex	− 0.024	0.882	(− 0.351 to 0.303)
Diagnose CD	− 0.291	0.101	(− 0.640 to 0.059)
Age at diagnosis	− 0.013	0.613	(− 0.063 to 0.038)
Albumin (g/L)	< − 0.001	0.938	(− 0.011 to 0.012)
CRP (mg/L)	0.003	0.379	(− 0.011 to 0.004)
ESR (mm/h)	− 0.004	0.270	(− 0.012 to < 0.004)
Clinical disease activity	− 0.014	0.845	(− 0.153 to 0.125)
ATI positive	− 0.681	< 0.001	(0.446 to 0.914)
Immunomodulator use	− 0.149	0.140	(− 0.348 to 0.049)
Dose (mg/kg)	0.050	0.051	(< 0.001 to 0.100)
Interval (days)	− 0.006	0.011	(− 0.010 to − 0.001)

Linear mixed model analysis is performed to investigate the influence of different predictors on IFX trough levels. p values < 0.05 were considered as significant

Abbreviations: B beta, sig. significant, CI confidence interval, CRP C-reactive protein, BSA body surface area, ESR erythrocyte sedimentation rate, IFX infliximab, ATI antibody to infliximab